Search results
Results from the WOW.Com Content Network
Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. [5] It is delivered subcutaneously either by injection or from an insulin pump .
Eli Lilly and Company developed and marketed the first rapid-acting insulin analogue (insulin lispro rDNA) Humalog. It was engineered through recombinant DNA technology so that the penultimate lysine and proline residues on the C-terminal end of the B-chain were reversed.
Lilly said that since then 10% of people using Humalog have transitioned to the cheaper injection. Lilly’s stock has risen 20.4% in the past year compared with 13.4% increase for the industry.
The shortage applies to the company's 10 mL vials of Humalog and Insulin Lispro Injection medications.
1983 Eli Lilly and Company produces biosynthetic human insulin with recombinant DNA technology, Humulin; 1985 Axel Ullrich sequences a human cell membrane insulin receptor. 1988 Novo Nordisk produces recombinant biosynthetic human insulin; 1996 Lilly Humalog "lispro" insulin analogue approved.
Drugmaker Eli Lilly warned this week that two of its formulations of insulin would be temporarily out of stock through the beginning of April, citing a “brief delay in manufacturing.”
[citation needed] Rapid-acting insulin analogs such as lispro (brand name Humalog, made by Eli Lilly and Company) and aspart (brand name Novolog/Novorapid, made by Novo Nordisk and Apidra made by Sanofi Aventis) are preferred by many clinicians over older regular insulin for meal coverage and high correction.
Americans without health insurance pay an average of $98 for Eli Lilly’s generic insulin despite the company’s May 1 pledge to cut its list price to $25 per vial, according to a survey of more ...